[Alternatives and further development of therapy of acute myeloid leukemia in adults. Update of West German multicenter studies].
The 1982 randomized, multicenter trial on adult-AML in West Germany revealed a superiority of remission duration (p = 0.004) and survival (p = 0.06) for patients receiving monthly myelosuppressive maintenance chemotherapy after TAD9-induction and consolidation as compared to patients without maintenance. In the 1985 pilot study double induction as a new approach followed by consolidation and monthly maintenance in patients up to 60 years of age was found well practicable, with 77% complete remissions and 12% early deaths in 81 patients. In addition preliminary remission duration and survival at 1 1/2 years appear favorable.
Büchner
T
T
Urbanitz
D
D
Hiddemann
W
W
Koch
P
P
Pielken
H J
HJ
Kuse
R
R
Mohr
A
A
Maschmeyer
G
G
Kreutzmann
H
H
Wendt
F
F
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D007167:Immunotherapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D011897:Random Allocation; D012074:Remission Induction
D003561:Cytarabine; D008942:Mitoxantrone
Alternativen und Weiterentwicklung der Therapie der akuten myeloischen Leukämie (AML) des Erwachsenen. Update der bundesdeutschen multizentrischen Studien.